stockrowInteger Holdings Corporation
ITGR Healthcare Medical Devices
Integer Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 7.98% from fiscal 2024.
- Revenue
- −3.86%
- EPS
- −61.0%
- Free cash flow
- −65.2%
- Total debt
- +4.06%
Quarter to September 2026, against a year earlier
Follow ITGR
Alert me
Integer Holdings Corporation (ITGR) EBITDA
Integer Holdings Corporation's EBITDA for fiscal 2025 was $358.8M, up 11.0% from $323.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was $296.5M. Over the past ten years it has ranged from $69.1M (fiscal 2015) to $358.8M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 3 consecutive fiscal years. Integer Holdings Corporation ranks 18th of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $358.8M | 10.98% |
| FY2024 | $323.3M | 19.65% |
| FY2023 | $270.2M | 30.73% |
| FY2022 | $206.7M | (7.74%) |
| FY2021 | $224.0M | 9.44% |
| FY2020 | $204.7M | (15.86%) |
| FY2019 | $243.3M | (17.15%) |
| FY2018 | $293.7M | 22.68% |
| FY2017 | $239.4M | 25.50% |
| FY2016 | $190.7M | 176.02% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $64.2M | (9.19%) |
| Jun 2026 | $70.7M | 3.21% |
| Mar 2026 | $68.5M | (26.41%) |
| Dec 2025 | $93.1M | 2.19% |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ITGR Integer Holdings Corporation | $296.5M |
| HAE Haemonetics Corporation compare | $273.8M |
| LIVN LivaNova PLC compare | $272.6M |
| TMDX TransMedics Group, Inc. compare | $126.9M |
| NEOG Neogen Corporation compare | $116.5M |
| UFPT UFP Technologies, Inc. compare | $116.0M |
| IRTC iRhythm Holdings, Inc. compare | $1.5M |
| AXGN AxoGen, Inc. compare | −$4.1M |
| TXG 10x Genomics compare | −$40.4M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ITGR
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement